Gabriella Allegri1, Sereina Deplazes1, Hiu Man Grisch-Chan1, Déborah Mathis2, Ralph Fingerhut3, Johannes Häberle4, Beat Thöny5. 1. Division of Metabolism and Children's Research Centre (CRC), University Children's Hospital Zurich, Switzerland. 2. Division of Clinical Chemistry and Biochemistry, University Children's Hospital Zurich, Switzerland. 3. Division of Metabolism and Children's Research Centre (CRC), University Children's Hospital Zurich, Switzerland; Swiss Newborn Screening Laboratory, University Children's Hospital Zurich, Switzerland. 4. Division of Metabolism and Children's Research Centre (CRC), University Children's Hospital Zurich, Switzerland; Zurich Centre for Integrative Human Physiology (ZIHP) and the Neuroscience Centre Zurich (ZNZ), Zurich, Switzerland. 5. Division of Metabolism and Children's Research Centre (CRC), University Children's Hospital Zurich, Switzerland; Zurich Centre for Integrative Human Physiology (ZIHP) and the Neuroscience Centre Zurich (ZNZ), Zurich, Switzerland. Electronic address: beat.thony@kispi.uzh.ch.
Abstract
BACKGROUND: Clinical management of inherited or acquired hyperammonemia depends mainly on the plasma ammonia level which is not a reliable indicator of urea cycle function as its concentrations largely fluctuate. The gold standard to assess ureagenesis in vivo is the use of stable isotopes. METHODS: Here we developed and validated a simplified in vivo method with [15N]ammonium chloride ([15N]H4Cl) as a tracer. Non-labeled and [15N]urea were quantified by GC-MS after extraction and silylation. RESULTS: Different matrices were evaluated for suitability of analysis. Ureagenesis was assessed in ornithine transcarbamylase (OTC)-deficient spfash mice with compromised urea cycle function during fasted and non-fasted feeding states, and after rAAV2/8-vector delivery expressing the murine OTC-cDNA in liver. Blood (5μL) was collected through tail vein puncture before and after [15N]H4Cl intraperitoneal injections over a two hour period. The tested matrices, blood, plasma and dried blood spots, can be used to quantify ureagenesis. Upon [15N]H4Cl challenge, urea production in spfash mice was reduced compared to wild-type and normalized following rAAV2/8-mediated gene therapeutic correction. The most significant difference in ureagenesis was at 30min after injection in untreated spfash mice under fasting conditions (19% of wild-type). Five consecutive injections over a period of five weeks had no effect on body weight or ureagenesis. CONCLUSION: This method is simple, robust and with no apparent risk, offering a sensitive, minimal-invasive, and fast measurement of ureagenesis capacity using dried blood spots. The stable isotope-based quantification of ureagenesis can be applied for the efficacy-testing of novel molecular therapies.
BACKGROUND: Clinical management of inherited or acquired hyperammonemia depends mainly on the plasma ammonia level which is not a reliable indicator of urea cycle function as its concentrations largely fluctuate. The gold standard to assess ureagenesis in vivo is the use of stable isotopes. METHODS: Here we developed and validated a simplified in vivo method with [15N]ammonium chloride ([15N]H4Cl) as a tracer. Non-labeled and [15N]urea were quantified by GC-MS after extraction and silylation. RESULTS: Different matrices were evaluated for suitability of analysis. Ureagenesis was assessed in ornithine transcarbamylase (OTC)-deficient spfash mice with compromised urea cycle function during fasted and non-fasted feeding states, and after rAAV2/8-vector delivery expressing the murineOTC-cDNA in liver. Blood (5μL) was collected through tail vein puncture before and after [15N]H4Cl intraperitoneal injections over a two hour period. The tested matrices, blood, plasma and dried blood spots, can be used to quantify ureagenesis. Upon [15N]H4Cl challenge, urea production in spfash mice was reduced compared to wild-type and normalized following rAAV2/8-mediated gene therapeutic correction. The most significant difference in ureagenesis was at 30min after injection in untreated spfash mice under fasting conditions (19% of wild-type). Five consecutive injections over a period of five weeks had no effect on body weight or ureagenesis. CONCLUSION: This method is simple, robust and with no apparent risk, offering a sensitive, minimal-invasive, and fast measurement of ureagenesis capacity using dried blood spots. The stable isotope-based quantification of ureagenesis can be applied for the efficacy-testing of novel molecular therapies.
Authors: Mihaela Zabulica; Tomas Jakobsson; Francesco Ravaioli; Massoud Vosough; Roberto Gramignoli; Ewa Ellis; Olav Rooyackers; Stephen C Strom Journal: Int J Mol Sci Date: 2021-01-26 Impact factor: 5.923
Authors: Brian Truong; Gabriella Allegri; Xiao-Bo Liu; Kristine E Burke; Xuling Zhu; Stephen D Cederbaum; Johannes Häberle; Paolo G V Martini; Gerald S Lipshutz Journal: Proc Natl Acad Sci U S A Date: 2019-09-09 Impact factor: 11.205
Authors: Mihaela Zabulica; Raghuraman C Srinivasan; Pinar Akcakaya; Gabriella Allegri; Burcu Bestas; Mike Firth; Christina Hammarstedt; Tomas Jakobsson; Towe Jakobsson; Ewa Ellis; Carl Jorns; Georgios Makris; Tanja Scherer; Nicole Rimann; Natalie R van Zuydam; Roberto Gramignoli; Anna Forslöw; Susanna Engberg; Marcello Maresca; Olav Rooyackers; Beat Thöny; Johannes Häberle; Barry Rosen; Stephen C Strom Journal: Mol Ther Date: 2021-01-21 Impact factor: 11.454
Authors: Leandro R Soria; Georgios Makris; Alfonso M D'Alessio; Angela De Angelis; Iolanda Boffa; Veronica M Pravata; Véronique Rüfenacht; Sergio Attanasio; Edoardo Nusco; Paola Arena; Andrew T Ferenbach; Debora Paris; Paola Cuomo; Andrea Motta; Matthew Nitzahn; Gerald S Lipshutz; Ainhoa Martínez-Pizarro; Eva Richard; Lourdes R Desviat; Johannes Häberle; Daan M F van Aalten; Nicola Brunetti-Pierri Journal: Nat Commun Date: 2022-09-05 Impact factor: 17.694